Biote (BTMD) vs Niagen Bioscience (NAGE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biote (BTMD) has outperformed Niagen Bioscience (NAGE) over the past year, losing 68.9% versus a loss of 73.3%. Over five years, NAGE leads with a -62.5% price change compared with -91.6% for BTMD. Niagen Bioscience is the larger company by market cap ($145.7 million vs $26.3 million), about 5.5 times the size.
Biote converts more of its revenue into profit, with a net margin of 14.1% versus 13.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BTMD | NAGE |
|---|---|---|
| Share price | $0.8147 | $1.84 |
| Market cap | $26.28M | $145.72M |
| 1-day change | -3.56% | -1.60% |
| YTD return | -68.67% | -71.07% |
| 1-year return | -68.90% | -73.26% |
| 5-year return | -91.64% | -62.53% |
| P/E ratio (TTM) | — | 15.33 |
| Forward P/E | 3.33 | — |
| EPS (TTM) | $-0.07 | $0.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $192.22M | $129.42M |
| Revenue growth (YoY) | -2.52% | +29.95% |
| Net income (latest FY) | $27.05M | $17.38M |
| Gross margin | 71.46% | 64.28% |
| Operating margin | 18.50% | 12.58% |
| Net margin | 14.07% | 13.43% |
| 52-week high | $2.90 | $7.11 |
| 52-week low | $0.81 | $1.79 |
| Distance from 52-week high | -71.91% | -74.12% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +220.36% | +479.89% |
| Average volume | 146.21K | 522.66K |
| Shares outstanding | 27.04M | 79.20M |
| Employees | 223 | 117 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Niagen Bioscience is about 5.5 times larger than Biote by market value ($145.72M vs $26.28M).
- Niagen Bioscience grew revenue faster in its latest fiscal year (+29.95% vs -2.52%).
About Biote
BTMD stock →biote Corp. operates in practice-building business within the hormone optimization space.
Health Care · Medicinal Chemicals and Botanical Products · 223 employees
About Niagen Bioscience
NAGE stock →Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products.
Health Care · Medicinal Chemicals and Botanical Products · 117 employees
BTMD vs NAGE FAQ
Which is bigger, Biote or Niagen Bioscience?
Niagen Bioscience (NAGE) is larger, with a market capitalization of $145.72M compared with $26.28M for Biote (BTMD).
Which stock has performed better over the past year, BTMD or NAGE?
BTMD returned -68.90% over the past 12 months, compared with -73.26% for NAGE (price return, excluding dividends). Past performance does not predict future results.
Are Biote and Niagen Bioscience in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.